Wendy Parulekar

Dr. Wendy Parulekar is a Senior Investigator at the Canadian Cancer Trials Group and Professor in the Department of Oncology at Queen's University. She completed her MD at the University of Ottawa Medical School, followed by residency in Internal Medicine and Medical Oncology (1996), and a fellowship in Clinical Pharmacology at Toronto Sunnybrook Regional Cancer Centre. Since 1999, she has held a joint clinical/research position at Queen's University.

Her research focuses on optimizing clinical trial design and methodology, particularly in breast, head/neck, and genitourinary cancers. She chairs the CCTG Education Committee and participates in national/international initiatives like the SPIRIT protocol standardization effort. Notable contributions include leading trials on SBRT for spinal metastases, ADT duration in prostate cancer, and biomarker-driven therapies for mCRPC.

Key awards include Fellow of the Society for Clinical Trials (2011). Current trials include PR21 (Lu-177 PSMA therapy), VU.2 STRIVE (vulvar SCC stratification), and ENZAMET (metastatic prostate cancer therapy).